Compare Hewlett Packard Enterprise Co (HPE) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hewlett Packard Enterprise Co vs Pfizer Inc — how do they compare? Hewlett Packard Enterprise Co trades at $71.61 (market cap $94.25B), while Pfizer Inc trades at $27.72 (market cap $158.56B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Hewlett Packard Enterprise Co for 33 Days and Pfizer Inc for 158 Days on average.
| HPE | PFE | |
|---|---|---|
Market Cap | $94.25B | $158.56B |
Volume | 16,060,854 | 44,138,282 |
Sector | Technology | Health |
52-Week High | $72.12 | $29.02 |
52-Week Low | $20.01 | $23.67 |
Typical Hold Time | 33 Days | 158 Days |
Enterprise Value | $108.28B | $210.06B |
Dividend Yield | 0.8% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPE's stock is trading at $72.12, up 2.2% today and near its all-time high, driven by strong AI infrastructure demand. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $1.11 surpassing the $0.932 estimate. The company secured a $1.2 billion AI server order from Vultr and raised its networking outlook, fueling bullish technical signals and positive analyst sentiment.
The outlook remains optimistic due to AI-driven growth and raised revenue targets, but risks include high valuation multiples and volatile cash flows. With a consensus price target of $70.35, slightly below the current price, the stock faces potential near-term resistance despite strong fundamentals and institutional upgrades.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
